Delivering a Better Path for Cancer Patients.

Giving Previously Untreatable Cancer Patients a Fighting Chance

We are developing targeted cancer treatments that offer effective therapy without harsh sideeffects so that even the most fragile patients can have tolerable treatment options.


Prognosis for fragile cancer patients remains very poor. Bio-Path aims to meet the need that exists for non-toxic therapies for fragile cancer patients who are ineligible for high-dose chemotherapy.


The company’s lead candidate is prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, for the treatment of acute myeloid leukemia (AML). Prexigebersen is being assessed in a Phase 2 trial in combination with front-line therapy. BP1001-A, a modified product of prexigebersen, incorporates the same drug substance as prexigebersen but has a slightly modified formulation designed to enhance nanoparticle properties for solid tumors. A Phase 1 trial is being conducted for BP1001-A in advanced solid tumors. The Company’s second product BP1002 (Liposomal Bcl-2 Antisense) is being evaluated in Phase 1 trials in lymphoma and AML

Our Products

Our pipeline consists of antisense RNAi nanoparticle drugs in clinical development for some of the most lethal blood cancers and solid tumors.